CC
CYTK icon

Centiva Capital’s Cytokinetics CYTK Stock Holding History

Centiva Capital’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$821K Buy
9,643
+6,643
+221% +$477K 0.01% 709
2026
Q1 		$198K Buy
+3,000
New +$191K ﹤0.01% 1281
2025
Q1 		– Sell
-4,905
Closed -$231K – 1652
2024
Q4 		$231K Sell
4,905
-1,595
-25% -$82.8K ﹤0.01% 1298
2024
Q3 		$343K Sell
6,500
-11
-0.2% -$613 0.01% 1495
2024
Q2 		$353K Sell
6,511
-9,989
-61% -$603K 0.01% 1380
2024
Q1 		$1.16M Buy
16,500
+16,205
+5,493% +$1.25M 0.03% 592
2023
Q4 		$24.6K Sell
295
-3,218
-92% -$117K ﹤0.01% 1665
2023
Q3 		$103K Buy
+3,513
New +$117K ﹤0.01% 1521
2023
Q2 		– Sell
-9,155
Closed -$322K – 1688
2023
Q1 		$322K Buy
+9,155
New +$373K 0.01% 1022

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Centiva Capital's CYTK Position: Q2 2026 in Review

Centiva Capital increased its Cytokinetics (CYTK) stake by 221% in Q2 2026, buying an estimated $477K and bringing the position to 9,643 shares worth $821K. The position accounts for 0.01% of the portfolio, ranked #709.

Centiva Capital first reported a position in CYTK in Q1 2023 and has held it in 9 quarters since. The position peaked at $1.16M in Q1 2024. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Centiva Capital held 9,643 shares of Cytokinetics worth $821K as of Q2 2026.
  • Centiva Capital bought 6,643 Cytokinetics shares in Q2 2026, an estimated $477K.
  • Cytokinetics made up 0.01% of Centiva Capital's portfolio in Q2 2026, its #709 holding.
  • Centiva Capital first reported a position in Cytokinetics in Q1 2023 and has held it in 9 quarters since.
  • Centiva Capital's Cytokinetics position peaked at $1.16M in Q1 2024.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Centiva Capital's 13F filing for Q2 2026, filed 13 Aug 2026.